CN117503935A - Application of hexokinase 2 inhibitor 3-BP in wound repair - Google Patents
Application of hexokinase 2 inhibitor 3-BP in wound repair Download PDFInfo
- Publication number
- CN117503935A CN117503935A CN202311518625.2A CN202311518625A CN117503935A CN 117503935 A CN117503935 A CN 117503935A CN 202311518625 A CN202311518625 A CN 202311518625A CN 117503935 A CN117503935 A CN 117503935A
- Authority
- CN
- China
- Prior art keywords
- protein
- inhibitor
- ionizing radiation
- radiation
- hexokinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229940119173 Hexokinase 2 inhibitor Drugs 0.000 title claims abstract description 5
- 230000037314 wound repair Effects 0.000 title abstract description 5
- 230000005865 ionizing radiation Effects 0.000 claims abstract description 56
- 102100029242 Hexokinase-2 Human genes 0.000 claims abstract description 42
- 239000003112 inhibitor Substances 0.000 claims abstract description 30
- 101710198385 Hexokinase-2 Proteins 0.000 claims abstract description 27
- 230000029663 wound healing Effects 0.000 claims abstract description 18
- 230000006907 apoptotic process Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 208000019155 Radiation injury Diseases 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 210000002514 epidermal stem cell Anatomy 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 25
- 239000000523 sample Substances 0.000 claims description 19
- 230000005855 radiation Effects 0.000 claims description 17
- 208000027418 Wounds and injury Diseases 0.000 claims description 14
- 206010052428 Wound Diseases 0.000 claims description 13
- 230000006378 damage Effects 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 102000004856 Lectins Human genes 0.000 claims description 5
- 108090001090 Lectins Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000002523 lectin Substances 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 229940121649 protein inhibitor Drugs 0.000 claims description 4
- 239000012268 protein inhibitor Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- -1 encapsulates Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 15
- 238000001514 detection method Methods 0.000 description 10
- 238000001574 biopsy Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108090000257 Cyclin E Proteins 0.000 description 2
- 102000003909 Cyclin E Human genes 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010051791 Nuclear Antigens Proteins 0.000 description 2
- 102000019040 Nuclear Antigens Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UKHILRWQZBMNKN-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound BrCC(C(=O)O)=O.BrCC(C(=O)O)=O UKHILRWQZBMNKN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 238000009012 ROS assay kit Methods 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 238000013275 image-guided biopsy Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 239000005304 optical glass Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000009396 radiation induced apoptosis Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of biological medicine, and in particular relates to an application of an inhibitor 3-BP of hexokinase 2 in wound repair. In particular, the invention provides an application of hexokinase 2 inhibitor 3-BP in preparing a medicament for promoting wound healing and preventing radiation injury. The function of reducing apoptosis and accelerating wound healing speed caused by ionizing radiation can be achieved by inhibiting hexokinase 2.
Description
Technical Field
The invention belongs to the field of biological medicine, and in particular relates to an application of an inhibitor 3-BP of hexokinase 2 in wound repair.
Background
Wound healing is a complex and orderly process involving hematopoietic cell responses, repair cell responses, extracellular matrix and growth factor responses, etc., where cell responses are key elements in the overall repair process. The pathological process of obviously delaying wound healing under the action of large-dose ionizing radiation is mainly characterized by: the hematopoiesis is restrained, the inflammatory reaction is weakened, especially inflammatory cells such as macrophages and neutrophils which are locally infiltrated by the wound are obviously reduced, and the wound starting process is delayed; vascular damage, endothelial cell degeneration, necrosis and obvious bleeding; the formation and maturation of granulation tissue are obviously slowed down, and the number and the function of fibroblast are damaged; and the epithelialization process is delayed, and the healing time is prolonged. In recent years, research from the molecular level further deepens the understanding of the mechanism of retarding wound healing by ionizing radiation. Studies have shown that reduced hematopoietic cell sources and increased radiation-induced apoptosis are important causes of reduced local inflammatory cell numbers in wounds, while radiation-induced cell proliferation inhibition and increased apoptosis are important causes of reduced fibroblast numbers. Proliferative nuclear antigen (proliferate cell nuclear antigen, PCNA), cyclin E (cyclin E), cyclin-dependent kinase 4 (CDK 4) and other molecules closely related to cell proliferation are reduced in expression, and cell cycle G is inhibited 1 The transition from phase S to phase S is an important mechanism responsible for the inhibition of cell proliferation; and the increase of expression of pro-apoptosis genes such as bax and the like and the decrease of expression of anti-apoptosis genes such as bcl-2 and the like are important mechanisms for causing the increase of apoptosis. Further studies have also found that cell counts are removedIn addition to the reduced amount, the cell functions are also obviously affected, and the synthesis and secretion of extracellular matrix molecules such as collagen, fibronectin and the like and growth factors such as basic fibroblast growth factors, transforming growth factor beta and the like are obviously reduced.
Hexokinase 2 (Hexokinase 2, hk 2) is a key metabolic enzyme that catalyzes the first step in the glycolytic pathway, phosphorylating glucose to glucose-6-phosphate, primarily localized on the outer mitochondrial membrane. HK2 exhibits high expression in many tumors and plays an important role in promoting the production of the Warburg effect. No research has reported that HK2 can promote wound healing after ionizing radiation.
Disclosure of Invention
According to the invention, by constructing an ionizing radiation model, the expression level of Hexokinase 2 (Hexokinase 2, HK 2) in human epidermal stem cells is increased after ionizing radiation, and the function of reducing the apoptosis degree caused by ionizing radiation of the inhibitor of the HK2 is further verified; moreover, animal model experiments prove that the application of 3-BP (3-bromopyruvate, 3-Bromopyruvic acid) which is an inhibitor of Hexokinase 2 (Hexokunase 2, HK 2) in advance can promote the healing of wound surfaces caused by ionizing radiation.
Based on the above purpose, the invention adopts the following technical scheme:
in one aspect, the invention provides an application of an inhibitor of hexokinase 2 in preparing a medicament for promoting wound healing and preventing radiation injury.
Further, the wound surface includes a wound surface caused by ionizing radiation.
Further, the radiation damage is damage caused by ionizing radiation, including but not limited to skin damage caused by ionizing radiation and other radioactive diseases. "ionizing radiation" as used in the present invention includes, in particular, radiation caused by the use of radioactive rays in radiotherapy (which may be simply referred to as radiotherapy). The types of radiation used in radiation therapy include alpha rays, beta rays, X rays, and gamma rays; wherein, the alpha rays and the beta rays are particle beams, and the X rays and the gamma rays are electromagnetic waves.
Further, the ionizing radiation refers to the use of 60 CoγRadiation from the radiation source.
In an embodiment of the present invention, the intensity of the ionizing radiation is 1 to 20Gy, preferably 5 to 8Gy, specifically including 1Gy, 2Gy, 3Gy, 4Gy, 5Gy, 6Gy, 7Gy, 8Gy, 9Gy, 10Gy, 11Gy, 12Gy, 13Gy, 14Gy, 15Gy, 16Gy, 17Gy, 18Gy, 19Gy, 20Gy. In a specific embodiment of the invention, the intensity of the ionizing radiation is 5Gy, 8Gy.
The abbreviation of Gy, namely "Gray", is a standard unit of the physical quantity "ionizing radiation energy absorbing dose". Gray may be interpreted as "Gray", "Golay", "Gray", and sometimes abbreviated as "Golay", and the concepts described above are intended to be used interchangeably herein.
Wound healing (Wound healing) refers to a series of pathophysiological processes in which local tissues are repaired by regeneration, repair and reconstruction after the tissue is lost due to the action of a Wound factor.
In the present invention, the term "inhibitor" refers to a molecule or substance or compound or composition or agent or any combination that is capable of inhibiting and/or reducing the activity or expression level of the target molecule.
Further, the inhibitors include nucleic acid inhibitors, protein inhibitors, proteolytic enzymes, protein binding molecules.
Further, the protein binding molecules include compounds.
Further, the protein binding agents also include, for example, receptors for proteins, lectins that bind proteins, antibodies to proteins, peptide antibodies (peptide bodies) to proteins, bispecific dual binding agents, or bispecific antibody formats.
Specifically, the inhibitor competitively or non-competitively binds with Hexokinase 2 (Hexokinase 2, hk 2), thereby achieving the function of inhibiting the biological activity of Hexokinase 2.
Further, the inhibitor is 3-BP or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof. The 3-BP is 3-bromopyruvate (3-Bromopyruvic acid). Further, the medicament also comprises a pharmaceutically acceptable carrier.
As used herein, a "pharmaceutically acceptable" ingredient is a substance that is suitable for use in humans and/or mammals without undue adverse side effects (such as toxicity, irritation, and allergic response), commensurate with a reasonable benefit/risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent.
Further, the pharmaceutically acceptable carrier includes diluents, buffers, suspensions, emulsions, granules, encapsulates, excipients, fillers, binders, sprays, transdermal absorbents, wetting agents, disintegrants, absorption enhancers, surfactants, colorants, flavoring agents, or adsorption carriers.
In another aspect, the invention provides the use of a reagent for detecting the amount of hexokinase 2 expressed in a sample from a subject in the manufacture of a product for diagnosing radiation damage, for diagnosing a radiation disease or for determining the severity of radiation damage to the skin.
Preferably, the subject is a mammal. Such as bovine, equine, ovine, porcine, canine, feline, rodent, primate, specifically such as human.
The term "sample" is defined as any material to be tested in the analytical or experimental methods described herein. In some embodiments, the sample is obtained via a non-invasive method (e.g., a non-invasive sample). Exemplary non-invasive methods include, but are not limited to, passive collection of bodily fluids or atraumatic scraping of tissue (e.g., of the epidermis or mouth) accessible from the external environment. Exemplary non-invasive samples include, but are not limited to, saliva, sputum, mucus, sweat, urine, stool, semen, cervical vaginal secretions, breast milk, inflammatory secretions, tears, or cheek epithelial swabs. In some embodiments, the sample is obtained via a micro-invasive method. Exemplary micro-invasive methods include, but are not limited to, capillary collection, venipuncture, thoracocentesis, amniocentesis, needle aspiration, or gastric lavage. Exemplary micro-invasive samples include, but are not limited to, blood or blood fractions (e.g., plasma or PBMC preparations), interstitial fluid, bile, gastric fluid, and amniotic fluid. In some embodiments, the sample is obtained via biopsy. Exemplary biopsy samples include, but are not limited to, skin biopsy samples (e.g., obtained by perforation, shaving, disk surgery, wedging, cutting, or resecting biopsy), bone marrow samples (e.g., obtained by aspiration biopsy), lymph node or breast biopsies (e.g., obtained by fine needle aspiration, core needle biopsy, vacuum assisted biopsy, or image guided biopsy), surgical biopsy samples (e.g., samples of internal organs obtained by resecting or resecting biopsy), or mouth, gastrointestinal tract, lung, bladder, or urinary tract biopsy samples (e.g., obtained by endoscopic examination).
Preferably, the sample comprises an epidermal cell; more specifically, epidermal stem cells.
Further, the radiation damage is damage caused by ionizing radiation.
Further, the radioactive disease is a disease caused by ionizing radiation.
Further, the diseases caused by the ionizing radiation comprise malignant tumors caused by the radiation and degenerative diseases caused by the radiation.
In the present invention, the malignant tumors caused by the irradiation include, but are not limited to, leukemia, skin cancer caused by external irradiation, thyroid cancer, bone malignant tumor, lung cancer caused by internal irradiation, bone malignant tumor, malignant tumor of liver and biliary tract system, and thyroid cancer.
In the present invention, the degenerative diseases caused by the radiation include, but are not limited to, cataract, aplastic anemia, osteonecrosis, osteoporosis, fibrosis of other body parts.
Further, the reagent comprises a reagent for detecting the expression level of hexokinase 2 by a digital imaging technology, a protein immunization technology, a dye technology, a nucleic acid sequencing technology, a nucleic acid hybridization technology, a chromatography technology and a mass spectrometry technology.
Further, the expression amount includes a protein expression amount and an mRNA expression amount, and preferably, a protein expression amount.
Further, the reagent comprises a primer, a probe and a protein binding agent.
Unless otherwise indicated, the term "primer" refers to an oligonucleotide that hybridizes to a sequence in a target nucleic acid ("primer binding site") and is capable of serving as a point to initiate synthesis along the complementary strand of the nucleic acid under conditions suitable for such synthesis.
Unless otherwise indicated, the term "probe" generally refers to a polynucleotide probe that is capable of binding to another polynucleotide (often referred to as a "target polynucleotide") by complementary base pairing. Depending on the stringency of the hybridization conditions, the probe is able to bind to a target polynucleotide that lacks complete sequence complementarity with the probe. The probes may be labeled directly or indirectly.
Unless otherwise indicated, the term "protein binding agent" is for example a receptor for a protein, a lectin that binds a protein, an antibody directed against a protein, a peptide antibody (peptide body) directed against a protein, a bispecific dual binding agent or a bispecific antibody format.
Further, the product comprises a chip, a kit or a nucleic acid membrane strip. In the present invention, a "chip" is also referred to as an "array" and refers to a solid support comprising attached nucleic acid or peptide probes. The array typically comprises a plurality of different nucleic acid or peptide probes attached to the surface of a substrate at different known locations. These arrays, also known as "microarrays," can generally be produced using mechanical synthesis methods or light-guided synthesis methods that combine a combination of photolithographic methods and solid-phase synthesis methods. The array may comprise a planar surface or may be a bead, gel, polymer surface, fiber such as optical fiber, glass or any other suitable nucleic acid or peptide on a substrate. The array may be packaged in a manner that allows for diagnosis or other manipulation of the fully functional device. The "microarray" is an ordered arrangement of hybridization array elements, such as polynucleotide probes (e.g., oligonucleotides) or binding agents (e.g., antibodies), on a substrate. The substrate may be a solid substrate, for example, a glass or silica slide, beads, a fiber optic binder, or a semi-solid substrate, for example, a nitrocellulose membrane. The nucleotide sequence may be DNA, RNA or any arrangement thereof.
Further, the kit comprises a gene detection kit and a protein detection kit.
Further, the kit may further comprise one or more of the following group: a container, instructions for use, positive control, negative control, buffer, adjuvant, or solvent.
In another aspect, the present invention also provides a method for detecting whether an epidermal stem cell is subjected to ionizing radiation, which comprises detecting the expression level of hexokinase 2 in the epidermal stem cell. Also, it may be referred to as a method of detecting whether a subject has been subjected to ionizing radiation, the epidermal stem cells being taken from the subject.
Further, the epidermal stem cell is an isolated epidermal stem cell or a commercial cell line.
Further, the method is performed in vitro or for non-diagnostic purposes. Specifically, in the method, an increase in the expression level of hexokinase 2 is indicative of exposure to ionizing radiation, more specifically, of 60 And (5) Co gamma ray irradiation.
In another aspect, the present invention also provides a method for inhibiting apoptosis of epidermal stem cells, which comprises inhibiting the expression level of hexokinase 2 in the epidermal stem cells.
Further, the method is performed in vitro or is not therapeutic.
Further, the inhibiting the expression level of hexokinase 2 in the epidermal stem cell comprises treating the epidermal stem cell with an inhibitor of hexokinase 2.
In another aspect, the invention also provides a method of promoting wound healing, preventing radiation damage, comprising administering to a subject an inhibitor of hexokinase 2. Further, the hexokinase 2 inhibitor is applied by application to the skin.
Further, the inhibitors include nucleic acid inhibitors, protein inhibitors, proteolytic enzymes, protein binding molecules.
Further, the protein binding molecules include compounds.
Further, the protein binding agents also include, for example, receptors for proteins, lectins that bind proteins, antibodies to proteins, peptide antibodies (peptide bodies) to proteins, bispecific dual binding agents, or bispecific antibody formats.
Further, the inhibitor is 3-BP or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.
More specifically, the 3-BP of the present invention is formulated using 3% methylcellulose as a solvent.
The invention has the beneficial effects that:
the invention discloses that the protein level of hexokinase 2 in human epidermal stem cells is obviously increased 48 hours after ionizing radiation treatment for the first time. The invention further proves that the HK2 inhibitor can reduce apoptosis caused by ionizing radiation through a cell experiment, and animal experiments prove that the HK2 inhibitor can promote wound healing. The invention provides a new method for promoting wound healing and has good clinical application prospect.
Drawings
FIG. 1 is a graph showing the results of immunoblotting for detecting protein levels of γH2A in human epidermal stem cells after ionizing radiation,
FIG. 2 is a graph showing the results of reactive oxygen species detection of human epidermal stem cells after ionizing radiation by ROS,
FIG. 3 is a graph showing the results of Tunel detection of apoptosis levels of human epidermal stem cells after ionizing radiation,
FIG. 4 shows the protein level of HK2 in human epidermal stem cells after detection of ionizing radiation by immunoblotting,
FIG. 5 is a graph showing the results of Tunel detection of apoptosis levels of human epidermal stem cells after 3-BP treatment,
FIG. 6 is a graph showing the results of 3-BP promoting wound healing after ionizing radiation.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
EXAMPLE 1 role of Hexokinase 2 (Hexokinase 2, HK 2) in wound repair
1. Experimental materials
1. Human epidermal stem cell line, stored in the laboratory (originally purchased from company);
2. ionizing radiation source: military medical institute 60 A Co gamma-ray source;
3. mice: for the C57BL/6J background, the culture was kept at room temperature (23 ℃) for 12 hours in a day-night period and allowed free ingestion and drinking water, purchased from Si Bei Fu (Beijing) Biotechnology Co., ltd;
4. inhibitors of HK2 3-BP (small compound) were purchased from selselect company;
5. ROS assay kit and apoptosis assay kit were purchased from Biyundian corporation.
2. Experimental method
1. Modeling and evaluation of ionizing radiation (Ionizing radiation, IR) damaged cells
Establishing an ionization injury cell model by using human epidermal stem cells, preparing single-cell suspension from the epidermal stem cells after digestion by pancreatin, and spreading the single-cell suspension in a cell culture plate; the next day cells were attached to the wall and the cell plates were placed 60 Irradiating under Co gamma rays, wherein the dose is 5Gy, and the irradiation dose is 79cGy/min; the irradiation time is about 6min, and then the sample is placed in an incubator, and samples are collected at different time points of 12h, D2 and the like for subsequent detection.
The acute phase DNA is damaged after ionizing radiation, while γh2ax is a DNA double strand break closely related, and is a marker of DNA damage, indicating whether the ionizing radiation cell model is successful.
2. ROS detection, apoptosis detection
The intracellular reactive oxygen species and apoptosis were analyzed using ROS kit and Tunel kit (bi yun) respectively, with reference to kit instructions.
3. Mouse ionizing radiation damage model
Male C57BL/6J mice were randomly divided into 4 groups, ctrl, ctrl+3-BP,After anesthesia with 2% tribromoethanol (intraperitoneal administration, 10 ul/g), the back hair was shaved off, and a round wound with a diameter of about 1cm was punched with a punch, and the results were obtained in the case of IR and IR+3-BP mice 60 And (3) carrying out local irradiation under Co gamma rays, wherein the dose is 8Gy, and a small compound 3-BP (prepared by using 3% methyl cellulose as a solvent) is smeared before irradiation, so as to record the wound healing condition.
3. Experimental results
1. Successfully build ionizing radiation model of human epidermal stem cells
As shown in fig. 1, human epidermal stem cells (EpSC) showed a significant increase in protein level of γh2a 0.5H after ionizing radiation (5 Gy), indicating DNA damage to the cells, which was successful in the ionizing radiation cell model.
2. Active oxygen in human epidermal stem cells increases after ionizing radiation, and cells undergo apoptosis
ROS detection results show that the human epidermal stem cells have significantly increased intracellular reactive oxygen species content and cell damage 2 days after ionizing radiation treatment. (as shown in FIG. 2)
Tunel test results show that the number of human epidermal stem cells is relatively obviously increased 3 days after ionizing radiation treatment, which indicates that cells undergo apoptosis after IR. (as shown in FIG. 3)
3. Increased expression of HK2 in epidermal stem cells in the acute phase after ionizing radiation
As shown in fig. 4, WB detection results show that 48 hours after ionizing radiation treatment, protein levels of HK2, a key limiting enzyme for sugar metabolism in cells, are significantly increased, suggesting that the cell sugar metabolism is disturbed after IR, and HK2, a key enzyme for metabolism, is abnormally increased, possibly involved in cell damage after IR.
4. The addition of the HK2 inhibitor 3-BP can reduce apoptosis of the epidermal stem cells
As shown in FIG. 5, the Tunel test results show that the number of human epidermal stem cells after the ionizing radiation treatment is relatively significantly increased, and the apoptosis is reduced after the treatment with the HK2 inhibitor 3-BP.
5. Application of HK2 inhibitor 3-BP in advance promotes wound healing after ionizing radiation
Establishing a mouse ionizing radiation skin injury model, smearing an HK2 inhibitor for 3-bp before IR, detecting wound healing conditions, and displaying the results: as shown in fig. 6, the IR group mice wound did not heal yet after 12 days of irradiation, and the ctrl and ir+ inhibitor groups wound healed better. This shows that HK2 plays an important role in the repair of ionizing radiation wound, and the use of its inhibitors can promote wound healing.
Although specific embodiments of the invention have been described in detail, those skilled in the art will appreciate that: many modifications and variations of the details are possible in light of the above teachings, and such variations are within the scope of the invention. The full scope of the invention is given by the appended claims and any equivalents thereof.
Claims (10)
1. Application of hexokinase 2 inhibitor in preparing medicine for promoting wound healing and preventing radiation injury;
preferably, the wound surface comprises a wound surface caused by ionizing radiation;
preferably, the radiation damage is damage caused by ionizing radiation; more preferably, skin lesions;
preferably, the ionizing radiation includes radiation caused by alpha rays, beta rays, X rays and gamma rays;
preferably, the ionizing radiation is 60 Radiation by Co gamma rays;
preferably, the intensity of the ionizing radiation is 1-20Gy or 5Gy-8 Gy;
preferably, the intensity of the ionizing radiation is 5Gy, 8Gy.
2. The use according to claim 1, wherein the inhibitor comprises a nucleic acid inhibitor, a protein inhibitor, a proteolytic enzyme or a protein binding molecule;
preferably, the protein binding molecule comprises a compound;
preferably, the protein binding molecules further comprise a receptor for a protein, a lectin that binds a protein, an antibody directed against a protein, a peptide directed against a protein;
preferably, the inhibitor is 3-BP or a stereoisomer, pharmaceutically acceptable salt, solvate or hydrate thereof.
3. The use of claim 1, wherein the medicament further comprises a pharmaceutically acceptable carrier;
preferably, the pharmaceutically acceptable carrier includes diluents, buffers, suspensions, emulsions, granules, encapsulates, excipients, fillers, binders, sprays, transdermal absorbents, wetting agents, disintegrants, absorption enhancers, surfactants, colorants, flavoring agents, or adsorption carriers.
4. Application of reagent for detecting hexokinase 2 expression in a subject sample in preparing products for diagnosing radiation injury, diagnosing radioactive diseases or judging skin radiation injury severity;
preferably, the expression amount includes a protein expression amount and an mRNA expression amount;
preferably, the radiation damage is damage caused by ionizing radiation;
preferably, the radioactive disease is a disease caused by ionizing radiation.
5. The use according to claim 4, wherein the reagent comprises a reagent for detecting the expression level of hexokinase 2 by digital imaging technique, protein immunization technique, dye technique, nucleic acid sequencing technique, nucleic acid hybridization technique, chromatography technique, mass spectrometry technique.
6. The method of claim 4, wherein the reagent comprises a primer, a probe, and a protein binding agent.
7. The use according to claim 4, wherein the product comprises a chip, a kit or a nucleic acid membrane strip.
8. A method for detecting whether an epidermal stem cell is subjected to ionizing radiation, comprising detecting the expression level of hexokinase 2 in the epidermal stem cell.
9. A method for inhibiting apoptosis of epidermal stem cells, comprising inhibiting expression of hexokinase 2 in the epidermal stem cells.
10. The method of claim 9, wherein the inhibitor comprises a nucleic acid inhibitor, a protein inhibitor, a proteolytic enzyme, or a protein binding molecule;
preferably, the protein binding molecule comprises a compound;
preferably, the protein binding molecules further comprise a receptor for a protein, a lectin that binds a protein, an antibody directed against a protein, a peptide directed against a protein;
preferably, the inhibitor is 3-BP or a stereoisomer, pharmaceutically acceptable salt, solvate or hydrate thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310624145.8A CN116726176A (en) | 2023-05-30 | 2023-05-30 | Medicine for repairing wound surface and application thereof |
CN2023106241458 | 2023-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117503935A true CN117503935A (en) | 2024-02-06 |
Family
ID=87910790
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310624145.8A Withdrawn CN116726176A (en) | 2023-05-30 | 2023-05-30 | Medicine for repairing wound surface and application thereof |
CN202311518625.2A Pending CN117503935A (en) | 2023-05-30 | 2023-11-15 | Application of hexokinase 2 inhibitor 3-BP in wound repair |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310624145.8A Withdrawn CN116726176A (en) | 2023-05-30 | 2023-05-30 | Medicine for repairing wound surface and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN116726176A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190142775A1 (en) * | 2016-05-03 | 2019-05-16 | Sciaderm, Inc. | Treating activated dermal conditions with agents that target energy metabolism |
WO2022006184A2 (en) * | 2020-06-29 | 2022-01-06 | Kodiscovery, Llc | Cellular energy inhibitor formulations for the treatment of pathogenic infections and associated methods |
-
2023
- 2023-05-30 CN CN202310624145.8A patent/CN116726176A/en not_active Withdrawn
- 2023-11-15 CN CN202311518625.2A patent/CN117503935A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190142775A1 (en) * | 2016-05-03 | 2019-05-16 | Sciaderm, Inc. | Treating activated dermal conditions with agents that target energy metabolism |
WO2022006184A2 (en) * | 2020-06-29 | 2022-01-06 | Kodiscovery, Llc | Cellular energy inhibitor formulations for the treatment of pathogenic infections and associated methods |
Non-Patent Citations (1)
Title |
---|
贺媛;吴桐;胡钦朝;夏娟;程斌;: "放射对口腔鳞癌细胞DNA损伤和糖酵解的影响", 中华老年口腔医学杂志, no. 04, 31 July 2016 (2016-07-31), pages 193 - 198 * |
Also Published As
Publication number | Publication date |
---|---|
CN116726176A (en) | 2023-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Garcia-Velasco et al. | Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis | |
JPH0213400A (en) | Estimation of effect of antitumor treatment in indivisual case | |
US20170283789A1 (en) | Methods for collecting cervical-vaginal fluids and isolating exosome and microvesicles for molecular analysis | |
CN108504658B (en) | Application of LINC01836 in preparation of gastric cancer diagnosis products and treatment medicines | |
Schena et al. | Cortical bone stem cell-derived exosomes’ therapeutic effect on myocardial ischemia-reperfusion and cardiac remodeling | |
CN105969901B (en) | Purposes of the MS4A6A as Huppert's disease diagnosis and treatment marker | |
Saed et al. | Differential expression of alpha smooth muscle cell actin in human fibroblasts isolated from intraperitoneal adhesions and normal peritoneal tissues | |
Jiang et al. | Mettl3-mediated m6A modification of Fgf16 restricts cardiomyocyte proliferation during heart regeneration | |
CN107312865B (en) | Purposes of the LOC100130111 in preparation osteosarcoma diagnostic products, therapeutic agent | |
CN107475386B (en) | Long-chain non-coding RNA marker for diagnosis and treatment osteosarcoma | |
CN105886659A (en) | DSTN gene and expression product thereof as diagnosis and treatment target of endometrial cancer | |
CN117503935A (en) | Application of hexokinase 2 inhibitor 3-BP in wound repair | |
CN105907879B (en) | Carcinoma of endometrium biomarker | |
CN108866181B (en) | Application of MBOAT1 gene in preeclampsia period | |
CN106947809A (en) | Application of the C6orf58 genes in Dendritic cell diagnosis and treatment product is prepared | |
CN106244705B (en) | Application of the ERC1 in preparation diagnosis or treatment hypopharyngeal cancer tool | |
CN105969904B (en) | Huppert's disease biomarker | |
CN105296657B (en) | Intracranial aneurysm diagnosis and treatment marker | |
CN110564846B (en) | TYW3 for diagnosing male osteoporosis | |
CN106119357B (en) | Application of the TNS11 in preparation diagnosis and treatment carcinoma of endometrium product | |
CN107365859B (en) | Molecular markers of the LncRNA as diagnosis and treatment osteosarcoma | |
CN106119358B (en) | The diagnosis and treatment product of carcinoma of endometrium biomarker | |
EP2137297A1 (en) | Methods for diagnosing biological samples containing stem cells | |
CN105543401B (en) | Gene marker relevant to fibroid | |
JPWO2007069423A1 (en) | Allergy diagnosis marker |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |